Abstract. Aberrant CpG island hypermethylation in gene promoter regions may be an important epigenetic event in human neoplasias, including breast cancer. Dietary and genetic factors that alter DNA methylation levels in normal and tumour tissues could therefore influence both the susceptibility to this disease and tumour phenotype, respectively. In the present study of 227 breast cancers, we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione ß-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome. However, tumours from patients who were homozygous for the methionine synthase A2756G polymorphism showed strikingly lower estrogen and progesterone hormone receptor concentrations compared to wild-type homozygotes. Moreover, patients who were homozygous for the methylene tetrahydrofolate dehydrogenase G1958A polymorphism showed a significantly higher frequency of tumour CpG island hypermethylation compared to wild-type homozygotes. Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.
Introduction
Methylation-induced transcriptional silencing of tumour suppressor genes is a major epigenetic mechanism leading to the inactivation of many important growth control genes during neoplastic development. This occurs via hypermethylation of CpG islands located in the 5'-promoter regions. Some of the genes reported to undergo hypermethylation-associated silencing in breast cancer include p16, estrogen receptor (ER), CDH1 and BRCA1 (1, 2) . The study of methylated gene targets has helped to elucidate the molecular pathogenesis of breast cancer and may also have clinical value for the early detection of this tumour type.
One of the major unanswered questions is whether germline factors can influence the level of hypermethylation observed in both normal and tumour tissues. In conjunction with environmental factors such as the level of dietary folate intake, this could contribute to the risk of cancer development. An example has been reported for the methionine synthase (MS) A2756G variant. Individuals who were homozygous for this polymorphism showed a lower frequency of CpG island hypermethylation in their tumour tissues (3) . Indeed, genes that are involved in methyl group metabolism such as MS represent good candidates for research into possible links between low-risk genetic factors and cancer. In addition to MS, other major genes in this pathway have common polymorphisms with known or suspected functional significance. These include a 28-bp tandem repeat in the enhancer region of thymidylate synthase (TS), the C677T polymorphism in methylene tetrahydrofolate reductase (MTHFR), a 68-bp insert in cystathione ß-synthase (CBS), the G1958A polymorphism in methylene tetrahydrofolate dehydrogenase (MTHFD1) and the C46359T polymorphism in DNA methyltransferase (DNMT3B). The role of these enzymes in methyl group metabolism is shown in Fig. 1 . The DNMT3B polymorphism alters enzyme activity (4) and could therefore be expected to directly influence the level of DNA hypermethylation. The other major enzymes involved in methyl group metabolism could influence DNA methylation indirectly by impacting the concentration of the major methyl group donor, S-adenosyl methionine. Studies indicate that polymorphisms in methyl group metabolism genes may contribute to the risk of colorectal cancer, possibly via effects on DNA methylation levels (5-7). Considerably less work has been carried out to establish whether these polymorphisms are linked to breast cancer risk or phenotype.
We recently evaluated a large series of sporadic human breast cancers for hypermethylation of CpG islands in the promoter regions of the RARß2, CDH1, ER, BRCA1, CCND2, p16 and TWIST genes (8) . In the current study, we investigated possible associations between the frequency of methylation at these sites and the presence of germ-line variants in the TS, MTHFR, MS, CBS, MTHFD1 and DNMT3B genes. We also determined whether these polymorphisms were associated with common pathological features of breast cancer or patient outcome from this disease. Our results suggest that certain genetic variants in methyl group metabolism may be associated with phenotypic features of breast cancer, however this does not appear to be mediated through the effects on DNA hypermethylation.
Materials and methods
Breast cancers. Tumour samples from a series of 227 primary invasive breast carcinoma patients undergoing elective surgery at the Sir Charles Gairdner Hospital in Western Australia between 1990 and 1994 were selected for this study. Genomic DNA was extracted from fresh frozen specimens using standard phenol-chloroform extraction procedures. The median age of patients at diagnosis was 59 years (range, 18-93 years) and the median follow-up time was 49 months (range, 2-78 months). Clinical and pathological features of this tumour series have been described earlier (9) . Diseasespecific survival data were obtained from the Death Registry, Health Department of Western Australia. At the end of the study, 38 (17%) patients had died from disease recurrence. Approximately 92% of node-positive and 23% of nodenegative patients received adjuvant systemic therapy comprising either hormone therapy alone or hormone therapy and chemotherapy. Approval for the study was obtained from the University of Western Australia Human Research Ethics Committee.
Genotype analyses. Genotyping for the TS promoter enhancer region (containing double and triple tandem repeats of 28 bp) and the MTHFR C677T polymorphisms were carried out using PCR and fluorescent PCR-SSCP, respectively, as described previously by our laboratory (10, 11) . The 844ins 68-bp polymorphism in CBS was determined by PCR and 2% agarose gel electrophoresis as described previously (7). PCR-RFLP was used to genotype single nucleotide polymorphisms (SNPs) in the DNMT3b (C46359T), MTHFD1 (G1958A) and MS (A2756G) genes. For the DNMT3b C46359T SNP, the primers 5'-ATGTCTGTC TGCTGTGACAGG-3' (forward) and 5'-TTGTTATTT CGAGTTCGGACC-3' (reverse) were used at an annealing temperature of 54˚C. The resulting 286-bp fragment was digested with AvrII (New England BioLabs) at 37˚C overnight followed by electrophoresis of digestion products on 2% agarose gels. PCR primers for the MTHFD1 G1958A SNP were 5'-CACTCCAGTGTTTGTCCATG-3' (forward) and 5'-GCATCTTGAGAGCCCTGAC-3' (reverse) and used at an annealing temperature of 62˚C. The 330-bp PCR product was digested with MspII (Promega) for 3 h at 37˚C followed by digestion analysis on 2% agarose gels. For the MS A2756G SNP, the primers 5'-TGTTCCCAGCTGTTA GATGAAAATC-3' (forward) and 5'-CTCCTTGAGAGA CTCATAATGG-3' (reverse) were used at a 60˚C annealing Common variants in these genes were examined for possible associations with phenotype and DNA methylation frequencies in breast cancer. Table I . Polymorphisms in methyl group metabolism genes and hormone receptor content of breast cancers.
In each case, the homozygous wild-type group is compared to the homozygous variant group, except for CBS, which was compared to the heterozygous group. b 3R, triple repeat; 2R, double repeat. c L, 68-bp insert; S, no 68-bp insert.
temperature. The 100-bp PCR product was digested with HaeIII (Promega) at 37˚C for 3 h before separation on 2.5% agarose gels.
Analysis of gene methylation status.
Hypermethylation at CpG islands in the 5' promoter regions of the RARß2, CDH1, ER, BRCA1, CCND2, p16 and TWIST genes was previously evaluated in 193 tumours from this breast cancer series using the PCR-MSP technique (8) . The frequency of methylation ranged from 11% for CCND2 to 84% for ER.
Statistical analysis. The Chi-square test was used to evaluate possible associations between genetic variants in CBS, DNMT3B, MTHFD1 and MS and various clinicopathological features. The Student's t-test was used to evaluate differences in hormone receptor content or gene methylation frequencies between different genotype groups. Patient survival was examined using Cox regression analysis. All tests were twotailed and statistical significance was assumed at P<0.05. The SPSS statistical software package (Chicago, IL, USA) was used throughout.
Results
Representative genotype analyses for CBS, DNMT3B, MTHFD1 and MS are shown in Fig. 2 . The variant allele frequencies were: CBS (68-bp insert, 0.08), DNMT3B C46359T (T allele, 0.47), MTHFD1 G1958A (A allele, 0.47) and MS A2756G (G allele, 0.20). All polymorphisms were in HardyWeinberg equilibrium. We have previously reported a lack of association between the conventional pathological features for this breast cancer series and both the TS 28-bp tandem repeat polymorphism and the MTHFR C677T polymorphism (10) . In the present study, no significant associations were observed between polymorphisms in the CBS, DNMT3B, MTHFD1 and MS genes and the clinicopathological features of patient age, tumour size, nodal status, histological grade or type. Breast cancers from patients who were homozygous for the MS A2756G polymorphism contained significantly lower concentrations of both estrogen and progesterone hormone receptors (Table I) . A trend was also observed for higher estrogen receptor concentrations in patients who were homozygous for the MTHFD1 G1958A polymorphism. No associations were observed between any of the common variants in methyl group metabolizing genes and patient survival from breast cancer.
We next examined whether polymorphisms in the methyl group metabolism genes were associated with the frequency of CpG island promoter methylation in 7 genes (RARß2, CDH1, ER, BRCA1, CCND2, p16 and TWIST) previously ONCOLOGY REPORTS 15: 221-225, 2006 223 Table II . Polymorphisms in methyl group metabolism genes and the frequency of CpG island promoter methylation in breast cancer.
-------------------------------------------------
Methylated sites Genotype (n) (mean ± SD) P- value  ----------------------------------------------- 
NS -------------------------------------------------a 3R/3R vs. 2R/2R;
b AA vs GG. evaluated for methylation by PCR-MSP (8) . Patients who were homozygous for the TS 28-bp double tandem repeat (2R/2R) showed a trend for more frequent promoter methylation in their breast cancers, while patients who were homozygous for the MTHFD1 G1958A polymorphism showed a significantly higher frequency of methylation (Table II) . None of the individual methylated CpG sites showed a significant association with any of the polymorphisms.
-------------------------------------------------

Discussion
Studies on colorectal cancer indicate that polymorphisms in key genes involved in methyl group and folate metabolism are likely to be associated with the risk for this tumour type (5-7), presumably via effects on DNA methylation or synthesis (Fig. 1) . Contradictory reports have been published for the risk of breast cancer associated with the MTHFR C677T polymorphism, with various studies suggesting protection (12) , no association (10, 13, 14) or increased risk (15) . Patient age, dietary folate intake and hormone replacement therapy were all found to be confounding factors in these studies.
In vitro and clinical studies showing that TS and MTHFR polymorphisms are associated with sensitivity to the chemotherapy agent 5-fluorouracil (16, 17) also support the contention that germ-line variants in methyl group metabolism play an important role in determining tumour biology. We recently evaluated the CpG island methylation status of 7 tumour suppressor genes in the current breast cancer series (8) . This allowed us in the present study to investigate whether common polymorphisms in 6 key genes involved in methyl group metabolism are associated with the frequency of DNA hypermethylation in breast cancer. In agreement with Paz et al (3), we found no evidence to suggest that the MTHFR C677T or CBS 68-bp insert polymorphisms were associated with CpG island hypermethylation in tumour DNA (Table II) . In contrast to that group, however, the MS A2756G polymorphism failed to show an association with methylation frequency in our study. This discrepancy could be due to the different tumour types examined and low number of GG homozygotes in both the Paz et al (n=5) and current (n=16) studies. Our results are also in agreement with another study in cervical cancer, which found no significant association between the MTHFR C677T or MS A2756G polymorphisms and the frequency of gene methylation (18) .
The only polymorphism found to show a significant association with the frequency of methylation in breast cancer was MTHFD1 G1958A (Table II) . It is not immediately obvious why this variant would be associated with CpG island methylation frequency, other than through a possible link with the concentration of intracellular folate intermediates. In support of this, in vitro studies in colorectal and gastric cell lines have shown a link between MTHFD1 expression and sensitivity to 5-fluorouracil (19, 20) . Further research is required, however, to evaluate DNA methylation and intracellular folate levels in relation to the MTHFD1 G1958A polymorphism in normal and tumour tissues.
DNMT3B is involved in the maintenance of DNA methylation, and hence the functional C46359T polymorphism in this gene (4) might be expected to show an association with increased frequency of CpG island promoter methylation in cancer. However, we found no evidence to support this in the current study of breast cancer (Table II) . A previous study reported a protective effect of the T allele against breast cancer (21) , whereas another found it was associated with increased incidence of lung cancer (4). Although we did not compare T allele frequencies between breast cancer and control individuals, our work suggests that any possible link between the DNMT3B polymorphism and risk for this disease is unlikely to be mediated through alterations in CpG island promoter methylation. Another study found that DNMT3B expression levels demonstrated strong prognostic value in breast cancer (22) . We found no evidence of prognostic significance for the DNMT3B C46359T polymorphism in the current study, suggesting this genetic variant may not be an important regulator of gene expression levels in breast cancer tissues.
An intriguing result from this study was the strong association between homozygosity for the MS A2756G polymorphism and low hormone receptor content (Table I) . This was the only significant association observed between any of the common polymorphisms in methyl group metabolism genes and clinicopathological features of breast cancer, including patient outcome. Methionine synthase converts homocysteine to methionine, a precursor for the universal methyl group donor, S-adenosyl methionine. The MS A2756G polymorphism was not associated with more frequent methylation of the ER gene (result not shown), and is therefore unlikely to provide an explanation for the association with lower ER concentration. Further studies carried out in independent tumour series are required to confirm the association between the MS 2756 GG genotype and low hormone receptor content observed here in breast cancer.
In conclusion, our study has shown that polymorphisms in two genes involved in methyl group metabolism, MS A2756G and MTHFD1 G1958A, are associated with hormone receptor status and DNA methylation frequency, respectively, in breast cancer. Additional studies in this area should aim to quantitatively evaluate the methylation levels in DNA from normal tissues of individuals with known folate intake and genotype status.
